DOCSLIB.ORG

800155000 22500Amx01833 B

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
800155000 22500Amx01833 B ࢯࣈࣜ࢔࣮ࢻ࢝ࣉࢭࣝ 100mg ࡟㛵ࡍࡿ㈨ᩱ ᮏ㈨ᩱ࡟グ㍕ࡉࢀࡓ᝟ሗ࡟ಀࡿᶒ฼ཬࡧෆᐜ࡟ࡘ࠸࡚ࡢ㈐௵ࡣࠊࣖࣥࢭࣥࣇ࢓࣮࣐ᰴᘧ ఍♫࡟ᖐᒓࡍࡿࡶࡢ࡛࠶ࡾࠊᙜヱ᝟ሗࢆᮏ⸆๣ࡢ㐺ṇ౑⏝௨እࡢႠ฼┠ⓗ࡟౑⏝ࡍࡿࡇ ࡜ࡣ࡛ࡁࡲࡏࢇࠋ ࣖࣥࢭࣥࣇ࢓࣮࣐ᰴᘧ఍♫ TMC435 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ ⋡ᰴ 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ ............................................................................................ 3 1.5.1 ⿠ේ෶ߪ⊒⷗ߩ⚻✲ ................................................................................................................ 3 1.5.2 ᧄ೷ߩኻ⽎∔ᖚ෸߮⥃ᐥ਄ߩ૏⟎ઃߌ ................................................................................ 3 1.5.2.1 C ဳᘟᕈ⢄Ἳߩ᭎ⷐ......................................................................................................... 3 1.5.2.2 C ဳᘟᕈ⢄Ἳߩᴦ≮ߩ⃻⁁ ............................................................................................. 3 1.5.3 㐿⊒ߩ⚻✲ ................................................................................................................................ 4 1.5.3.1 ຠ⾰ߦ㑐ߔࠆ⹜㛎ߩ᭎⇛ ................................................................................................ 4 1.5.3.2 㕖⥃ᐥ⹜㛎ߩ᭎⇛ ............................................................................................................ 5 1.5.3.3 ⥃ᐥ㐿⊒ߩ᭎⇛ ................................................................................................................ 6 1.5.4 ᧄ೷ߩ੍ᗐߐࠇࠆᴦ≮਄ߩ૏⟎ઃߌ .................................................................................. 11 JEDI_DEV00 \ 0900fde980400983 2.4 2013-08-19 13:38 1 TMC435 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ ⇛ภ৻ⷩ⴫ ⇛ภ෶ߪ⇛⒓ ൻቇฬ෶ߪ৻⥸ฬ ᭴ㅧᑼ ↱᧪ Monosodium O CH3 (cyclopropylsulfonyl)[(2R,3aR,10Z,11aS, O S O CH 12aR,14aR)-2-({7-methoxy-8-methyl-2-[4- O NNa 3 O (1-methylethyl)-1,3-thiazol-2-yl]quinolin- H N N H TMC435 4-yl}oxy)-5-methyl-4,14-dioxo- CH ਥ⮎ H 3 H O N 1,2,3,3a,4,5,6,7,8,9,11a,12,12a,13,14,14a- H hexadecahydrocyclopenta[c]cyclopropa[g] S CH3 [1,6]diazacyclotetradecine-12a- N O carbonyl]azanide CH3 ⇛ภ෶ߪ⇛⒓ ฬ⒓෸߮ౝኈ ALT alanine aminotransferase㧔ࠕ࡜࠾ࡦࠕࡒࡁ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯㧕 AST aspartate aminotransferase㧔ࠕࠬࡄ࡜ࠡࡦ㉄ࠕࡒࡁ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯㧕 BCOP bovine corneal opacity-permeability㧔࠙ࠪⷺ⤑ᷙỘ෸߮ㅘㆊᕈ㧕 CYP cytochrome P450㧔࠴࠻ࠢࡠ࡯ࡓ P450㧕 GCP Good Clinical Practice㧔ක⮎ຠߩ⥃ᐥ⹜㛎ߩታᣉߩၮḰ㧕 GLP Good Laboratory Practice㧔ක⮎ຠߩ቟ోᕈߦ㑐ߔࠆ㕖⥃ᐥ⹜㛎ߩታᣉߩၮḰ㧕 HCV hepatitis C virus㧔C ဳ⢄Ἳ࠙ࠗ࡞ࠬ㧕 HIV human immunodeficiency virus㧔ࡅ࠻఺∉ਇో࠙ࠗ࡞ࠬ㧕 The International Conference on Harmonisation of Technical Requirements for Registration ICH of Pharmaceuticals for Human Use㧔ᣣ☨ EU ක⮎ຠⷙ೙⺞๺࿖㓙ળ⼏㧕 IFN interferone㧔ࠗࡦ࠲࡯ࡈࠚࡠࡦ㧕 IL28B interleukin-28B㧔ࠗࡦ࠲࡯ࡠࠗࠠࡦ㧙28B㧕 LLNA local lymph node assay㧔ዪᚲ࡝ࡦࡄ▵⹜㛎㧕 PegIFN peginterferon㧔ࡍࠣࠗࡦ࠲࡯ࡈࠚࡠࡦ㧕 PegIFNĮ-2a peginterferon alfa-2a㧔ࡍࠣࠗࡦ࠲࡯ࡈࠚࡠࡦࠕ࡞ࡈࠔ-2a㧕 PegIFNĮ-2b peginterferon alfa-2b㧔ࡍࠣࠗࡦ࠲࡯ࡈࠚࡠࡦࠕ࡞ࡈࠔ-2b㧕 P-gp P-glycoprotein㧔P-♧ߚࠎ⊕⾰㧕 time interval between the start of the Q wave and the end of the T wave in cardiac electrical QT cycle㧔ᔃ㔚࿑ QT㧕 JEDI_DEV00 \ 0900fde980400983 2.4 2013-08-19 13:38 QTc QT interval corrected for heart rate㧔ᔃ㔚࿑ QT ⵬ᱜ୯㧕 RBV ribavirin㧔࡝ࡃࡆ࡝ࡦ㧕 RGT response-guided therapy RNA ribonucleic acid㧔࡝ࡏᩭ㉄㧕 SVR sustained virologic response㧔ᜬ⛯⊛࠙ࠗ࡞ࠬ㒶ᕈൻ㧕 㧨⥃ᐥ⹜㛎ߩ⹜㛎⇟ภߩᮡ⸥ߦߟ޿ߡ㧪 ⥃ᐥ⹜㛎ߩ⹜㛎⇟ภߪ㧘TMC435 ߩ㐿⊒ᤨᦼߦࠃߞߡᰴߩ 3 ㅢࠅߩᣇᴺߢઃਈߐࠇߚ㧔XXX ෸ ߮ XXXX ߪ㧘ߘࠇߙࠇ 3 ᩴ෸߮ 4 ᩴߩ࿕᦭ߩᢙሼ㧕ޕᧄ⾗ᢱߢߪ㧘ฦ⹜㛎⇟ภߪޟCXXXޠ෶ߪ ޟHPCXXXXޠߢ␜ߔޕ · TMC435350-TiDP16-CXXX㧔㐿⊒ೋᦼߩ⹜㛎ߦ૶↪㧕 · TMC435-TiDP16-CXXX · TMC435HPCXXXX㧔ᦨㄭߩ⹜㛎ߦ૶↪㧕 2 TMC435 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ 1.5.1 ⿠ේ෶ߪ⊒⷗ߩ⚻✲ TMC435㧔ࠪࡔࡊ࡟ࡆ࡞࠽࠻࡝࠙ࡓ㧕ߪ㧘C ဳ⢄Ἳ࠙ࠗ࡞ࠬ㧔એਅ㧘HCV㧕ᗵᨴ∝ߦኻߔࠆᴦ ≮⮎ߣߒߡ㧘Medivir ␠෸߮ Tibotec Pharmaceuticals Ltd.㧔⃻ Janssen R&D Ireland㧕ߦࠃࠅ౒ห㐿 ⊒ߐࠇߚ╙ੑ਎ઍߩࡊࡠ࠹ࠕ࡯࠯㒖ኂ⮎ߢ޽ࠆޕTMC435 ߪᄢⅣ⁁᭴ㅧࠍ᦭ߒ㧘HCV ߩⶄ⵾ߦᔅ 㗇ߢ޽ࠆ NS3/4A ࠮࡝ࡦࡊࡠ࠹ࠕ࡯࠯ߣ㕖౒᦭⚿วߔࠆߎߣߦࠃࠅ․⇣⊛ߦߘߩᵴᕈࠍ㒖ኂߒߡ ᛫࠙ࠗ࡞ࠬ૞↪ࠍ␜ߔޕTMC435 ߩ᭴ㅧᑼࠍ࿑ 1.5-1 ߦ␜ߔޕ O CH O S O 3 CH O NNa 3 O H N N H CH3 H N H O H S CH3 N O CH3 ࿑ 1.5-1 TMC435 ߩ᭴ㅧᑼ 1.5.2 ᧄ೷ߩኻ⽎∔ᖚ෸߮⥃ᐥ਄ߩ૏⟎ઃߌ 1.5.2.1 C ဳᘟᕈ⢄Ἳߩ᭎ⷐ HCV ᗵᨴߪ㧘ో਎⇇ߢ⢄∔ᖚߩਥⷐߥේ࿃ߣߥߞߡ߅ࠅ㧘ߘߩᗵᨴ⠪ᢙߪ⚂ 1 ం 7000 ਁੱ㧘 ࿖ౝߢߪ 150 ਁੱએ਄ሽ࿷ߔࠆߣផቯߐࠇߡ޿ࠆ 1㧕ޕHCV ߦᗵᨴߔࠆߣኋਥ஥ߩ఺∉ᔕ╵ߦࠃ JEDI_DEV00 \ 0900fde980400983 2.4 2013-08-19 13:38 ࠅᕆᕈ⢄Ἳࠍ⊒∝ߒߚᓟ㧘ήᴦ≮ߩ႐ว 55㨪85%ߩᖚ⠪ߪ HCV ߇ឃ㒰ߐࠇߕᘟᕈ⢄Ἳ߳ߣ⒖ⴕ ߒ㧘⢄✢⛽ൻ߇✭ᓢߦㅴⴕߒ㧘20㨪25 ᐕߢ 5㨪20%ߩᖚ⠪ߪ⢄⎬ᄌߦ⥋ࠆޕ⢄⎬ᄌߪᦨ⚳⊛ߦ⢄ ਇో߿⢄⚦⢩≸ߦ⥋ࠆ㊀◊ߥォᏫࠍߚߤࠆ∔ᖚߢ޽ࠅ㧘⢄⎬ᄌ߆ࠄߩ⢄⚦⢩≸⊒∝₸ߪ᰷☨ߩᐕ 1㨪4%ߦᲧߒ࿖ౝߢߪᐕ 7%ߣ㜞޿ޕ߹ߚ㧘࿖ౝߢߩ⢄⚦⢩≸ߩᐕ㑆ᱫ੢⠪ߩ⚂ 80%߇ C ဳᘟᕈ ⢄Ἳ߆ࠄ⒖ⴕߒߚ߽ߩߣ⠨߃ࠄࠇߡ޿ࠆ 2㧕3㧕ޕC ဳᘟᕈ⢄Ἳߩ⥄ὼᴦ≹ߪᭂ߼ߡ⒘ߢ޽ࠅ㧘⢄ታ ⾰ౝߢߩ⢄⚦⢩ߩᄌᕈ෸߮უᱫᚲ⷗㧘ਗ߮ߦ㐷⣂ၞߦߪ࡝ࡦࡄ⃿ࠍਥ૕ߣߒߚἻ∝ᕈ⚦⢩ᶐẢߣ ✢⛽ൻ߇⃻ࠇ㧘ᜬ⛯⊛ߥ⢄ᯏ⢻⇣Ᏹࠍ๒ߔࠆޕ 1.5.2.2 C ဳᘟᕈ⢄Ἳߩᴦ≮ߩ⃻⁁ C ဳᘟᕈ⢄Ἳᴦ≮ߩਥߚࠆ⋡ᮡߪ㧘⢄Ἳߩᴉ㕒ൻߦࠃࠅ✢⛽ൻߩㅴⴕࠍᛥ߃㧘⢄⎬ᄌ෶ߪ⢄⚦ ⢩≸߳ߩㅴዷࠍ㒐ߋߎߣߢ޽ࠅ㧘ߘߩߚ߼ߦᦨ߽ലᨐ⊛ߥᴦ≮ߣߒߡ࠙ࠗ࡞ࠬឃ㒰߇㊀ⷐߣ⠨߃ ࠄࠇߡ߅ࠅ㧘․ߦ㧘㜞㦂⠪߿✢⛽ൻㅴዷ଀ࠍ฽߻㜞⊒߇ࠎ࡝ࠬࠢ⟲ߢߪ㧘ᣧᦼߦ᛫࠙ࠗ࡞ࠬ≮ᴺ ߇⠨ᘦߐࠇࠆߴ߈ߣߐࠇࠆ 1㧕ޕ ࿖ౝߦ߅޿ߡ㧘1992 ᐕߦࠗࡦ࠲࡯ࡈࠚࡠࡦ㧔એਅ㧘IFN㧕⵾೷߇࠙ࠗ࡞ࠬឃ㒰ࠍ⋡⊛ߣߒߚ C ဳᘟᕈ⢄Ἳߩᴦ≮⮎ߣߒߡ଻㒾ㆡ↪ߐࠇ㧘ߘߩᓟ࡝ࡃࡆ࡝ࡦ㧔એਅ㧘RBV㧕ߣߩ૬↪≮ᴺ߿ࡍࠣ 3 TMC435 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ ࠗࡦ࠲࡯ࡈࠚࡠࡦ㧔એਅ㧘PegIFN㧕⵾೷߇㐿⊒ߐࠇ㧘HCV Genotype ߦᔕߓߡᛩਈᦼ㑆߇ᦨㆡൻ ߐࠇߚޕ ߎࠇ߹ߢ㧘PegIFN ෸߮ RBV ߩ 2 ೷≮ᴺߪ㧘㔍ᴦᕈߩ Genotype 1 ဳߢ㜞࠙ࠗ࡞ࠬ㊂ߩᖚ⠪ߦኻ ߔࠆᮡḰ≮ᴺߢ޽ߞߚ߽ߩߩ㧘SVR24 ₸㧔ᛩਈ⚳ੌᤨ෸߮ᛩਈ⚳ੌᓟ 24 ㅳߩⴊẏਛ HCV RNA ߇㒶ᕈൻߒߚⵍ㛎⠪ߩഀว㧕ߪ 50%⒟ᐲߢ޽ߞߚ 4㧕ޕ߹ߚ㧘ਥߥ᦭ኂ੐⽎ߪ㧘⊒ᾲ㧘ୱᕃᗵ㧘 㗡∩╬ߩࠗࡦࡈ࡞ࠛࡦࠩ᭽∝⁁ߢ޽ࠅ㧘᦭ኂ੐⽎߿⥃ᐥᬌᩏ୯⇣Ᏹߩߚ߼ߦᄙߊߩᖚ⠪߇ᷫ㊂෶ ߪભ⮎ߦ⥋ࠅ㧘12㨪16%ߩᖚ⠪߇ᴦ≮ࠍਛᱛߒߚ 4㧕ޕᦝߦ㧘ᴦ≮ᦼ㑆߇ 48 ㅳ㑆㧔ലᨐਇචಽߥ ႐วߪ 72 ㅳ㑆߹ߢᑧ㐳㧕ߣ㐳ߊ㧘ᖚ⠪ߩᔃり߳ߩ⽶ᜂߪᄢ߈߆ߞߚޕߘߩߚ߼㧘ᴦ≮ലᨐߩะ ਄㧘቟ోᕈ෸߮ᔋኈᕈߩᡷༀ㧘ਗ߮ߦᴦ≮ᦼ㑆ߩ⍴❗߇⺖㗴ߢ޽ߞߚޕ߹ߚ㧘PegIFN ෸߮ RBV ߩ 2 ೷≮ᴺߢౣΆ෶ߪήലߢ޽ߞߚᖚ⠪ߦኻߒߡ㧘ᛩਈᦼ㑆ߩᑧ㐳߽฽߼ߚ PegIFN ෸߮ RBV ߦ ࠃࠆౣᴦ≮ᤨߩ SVR24 ₸ߪ㧘೨ᴦ≮ౣΆ଀ߢ 50%㧘೨ᴦ≮ήല଀ߢߪ 14%⒟ᐲߣߐࠇ 5㧕6㧕㧘․ ߦ೨ᴦ≮ήല଀ߦኻߔࠆ᦭ലߥ᛫࠙ࠗ࡞ࠬ≮ᴺߪታ⾰ߥ߆ߞߚޕ 2011 ᐕߦ NS3/4A ࠮࡝ࡦࡊࡠ࠹ࠕ࡯࠯㒖ኂ೷ߢ޽ࠆ࠹࡜ࡊ࡟ࡆ࡞߇࿖ౝߢᛚ⹺ߐࠇ㧘PegIFNĮ- 2b ෸߮ RBV ߣߩ 3 ೷૬↪≮ᴺ߇ዉ౉ߐࠇߚޕ࠹࡜ࡊ࡟ࡆ࡞ࠍട߃ߚ 3 ೷૬↪≮ᴺߦࠃࠅ㧘ᴦ≮ ലᨐߪะ਄ߒ㧘✚ᴦ≮ᦼ㑆߇ 24 ㅳ㑆ߦ⍴❗ߐࠇ㧘C ဳᘟᕈ⢄Ἳߩᴦ≮ߪᄢ᏷ߦᡷༀߐࠇߚ 7㧕8㧕ޕ ߒ߆ߒߥ߇ࠄ㧘㊀◊ߥ⊹⤏㓚ኂ߿⽺ⴊ╬ߩ೽૞↪ߩߚ߼㧘቟ోᕈ਄ߩ ᔨߦࠃࠆಣᣇ೙㒢߿೽૞ ↪߳ߩኻᔕߥߤ㧘ᣂߚߥ⺖㗴߽಴ߡ߈ߡ޿ࠆޕ߹ߚ㧘࠹࡜ࡊ࡟ࡆ࡞ߩ࿖ౝ⥃ᐥ⹜㛎ߢߪ 65 ᱦࠍ ⿥߃ࠆᖚ⠪ߪኻ⽎ߣߐࠇߡ߅ࠄߕ㧘ᣣᧄ⢄⤳ቇળߦࠃࠆޟC ဳ⢄Ἳᴦ≮ࠟࠗ࠼࡜ࠗࡦޠ1㧕ߦ߅޿ ߡ㧘࠹࡜ࡊ࡟ࡆ࡞㧘PegIFNĮ-2b ෸߮ RBV ߩ 3 ೷૬↪≮ᴺߪ Genotype 1 ဳ㜞࠙ࠗ࡞ࠬ㊂ߩ C ဳᘟ ᕈ⢄Ἳᖚ⠪ߩ߁ߜ㕖㜞㦂⠪ࠍၮᧄߦㆡᱜߥᖚ⠪ࠍ⷗ᭂ߼ߚ਄ߢ૶↪ߔࠆߎߣ߇ផᅑߐࠇߡ߅ࠅ㧘 㕖㜞㦂⠪ߦ߅޿ߡ߽㧘IL28B ㆮવሶᄙဳ㧔SNP rs8099917㧕߇ࡑࠗ࠽࡯ࠕ࡟࡞㧔TG ෶ߪ GG㧕ߢ HCV ࠦࠕ㗔ၞ 70 ⇟ࠕࡒࡁ㉄߇ᄌ⇣ဳߩᖚ⠪ߦኻߒߡߪផᅑߐࠇߡ޿ߥ޿ޕ 1.5.3 㐿⊒ߩ⚻✲ JEDI_DEV00 \ 0900fde980400983 2.4 2013-08-19 13:38 TMC435 ߩ㐿⊒ߩ⚻✲࿑ࠍ࿑ 1.5-2 ෸߮࿑ 1.5-3 ߦ␜ߔޕ 1.5.3.1 ຠ⾰ߦ㑐ߔࠆ⹜㛎ߩ᭎⇛ (1) ේ⮎ ේ⮎ߩ▤ℂߪࠪࡔࡊ࡟ࡆ࡞ߢⴕ߁ޕታ↢↥ߦ↪޿ࠆ⵾ㅧᣇᴺߢ⵾ㅧߒߚࠪࡔࡊ࡟ࡆ࡞ߪ㧘㐳ᦼ ଻ሽ⹜㛎㧔25°C/60%RH㧕෸߮ടㅦ⹜㛎㧔40°C/75%RH㧕ߦ߅޿ߡ㧘ߘࠇߙࠇ 18 ࠞ᦬㑆෸߮ 6 ࠞ ᦬㑆቟ቯߢ޽ߞߚޕ⧦㉃⹜㛎㧔50°C/3 ࠞ᦬㧕ߦ߅޿ߡࠪࡔࡊ࡟ࡆ࡞ߦ⚻ᤨ⊛ߥᄌൻߪ⹺߼ࠄࠇߥ ߆ߞߚ߽ߩߩ㧘⧦㉃⹜㛎㧔ᦑశ/ICH Q1B ߦḰ᜚㧕ߦ߅޿ߡᕈ⁁ߩᄌൻ㧘฽㊂ߩૐਅ෸߮ಽ⸃‛ ߩ↢ᚑ߇⹺߼ࠄࠇߚޕએ਄ߩ⚿ᨐߦၮߠ߈㧘ࠪࡔࡊ࡟ࡆ࡞ߩ࡝࠹ࠬ࠻ᦼ㑆ࠍ ࠞ᦬㧔ቶ᷷㧘ㆤ శ଻ሽ㧕ߦ⸳ቯߒߚޕ 4 TMC435 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ (2) ⵾೷ ᧄ೷ߪ㧘1 ࠞࡊ࠮࡞ਛߦࠪࡔࡊ࡟ࡆ࡞࠽࠻࡝࠙ࡓ 102.93 mg㧔ࠪࡔࡊ࡟ࡆ࡞ߣߒߡ 100 mg㧕ࠍ ฽᦭ߔࠆ⎬ࠞࡊ࠮࡞೷ߢ޽ࠆޕᧄ೷ߦᣂⷙᷝട೷ߪ૶↪ߒߡ޿ߥ޿ޕ ᧄ೷ߪ㧘㐳ᦼ଻ሽ⹜㛎㧔25°C/60%RH㧕෸߮ടㅦ⹜㛎㧔40°C/75%RH㧕ߦ߅޿ߡ㧘 ߩჇട߇ ⹺߼ࠄࠇߚ߽ߩߩ㧘ߘࠇߙࠇ 12 ࠞ᦬㑆෸߮ 6 ࠞ᦬㑆቟ቯߢ޽ߞߚޕ⧦㉃⹜㛎㧔50°C/3 ࠞ᦬㧕ߦ ߅޿ߡ⚻ᤨ⊛ߥᄌൻߪ⹺߼ࠄࠇߥ߆ߞߚޕ⧦㉃⹜㛎㧔ᦑశ/ICH Q1B ߦḰ᜚㧕ߢߪ㧘ή൮ⵝຠߦ ߅޿ߡಽ⸃‛ߩࠊߕ߆ߥჇട෸߮฽㊂ߩૐਅ߇⹺߼ࠄࠇߚ߇㧘৻ᰴ൮ⵝຠߢߪ቟ቯߢ޽ߞߚޕએ ਄ߩ⚿ᨐߦၮߠ߈㧘ᧄ೷ߩ᦭ലᦼ㑆ࠍ 24 ࠞ᦬㧔ቶ᷷㧘ㆤశ଻ሽ㧕ߦ⸳ቯߒߚޕ 1.5.3.2 㕖⥃ᐥ⹜㛎ߩ᭎⇛ 1.5.3.2.1 ⮎ℂ⹜㛎 ലജࠍⵣઃߌࠆ⹜㛎ߣߒߡ㧘HCV NS3/4A ࡊࡠ࠹ࠕ࡯࠯ߦ⚿วߒߚࠪࡔࡊ࡟ࡆ࡞ߩ⚿᥏᭴ㅧࠍ ⸃ᨆߔࠆߣߣ߽ߦ㧘HCV NS3/4A ࡊࡠ࠹ࠕ࡯࠯ߦኻߔࠆ㉂⚛ቇ⊛㒖ኂ૞↪㧘࡟ࡊ࡝ࠦࡦ⚦⢩ࠍ↪ ޿ߚ᛫࠙ࠗ࡞ࠬ૞↪㧘ࡅ࠻෸߮േ‛⚦⢩ߦኻߔࠆ૞↪㧘HCV એᄖߩ࠙ࠗ࡞ࠬߦኻߔࠆ૞↪㧘 retinoic acid-inducible gene I ෸߮ toll-like receptor 3 ଐሽᕈ IFN ↥↢♽ߦኻߔࠆ૞↪㧘ઁߩ᛫ HCV ⮎෶ߪ᛫ࡅ࠻ ఺∉ਇో ࠙ࠗ࡞ࠬ㧔એਅ㧘HIV㧕⮎ߣߩ૬↪૞↪㧘ਗ߮ߦ⮎೷⠴ᕈߦ㑐ߔࠆᬌ⸛ ࠍⴕߞߚޕ೽ᰴ⊛⮎ℂ⹜㛎ߣߒߡ㧘ฦ⒳ฃኈ૕෸߮࠴ࡖࡀ࡞ߦኻߔࠆ in vitro ૞↪㧘ਗ߮ߦฦ⒳ ᯏ⢻෸߮⚵❱ߦኻߔࠆ in vitro ෸߮ in vivo ૞↪ࠍᬌ⸛ߒߚޕ቟ోᕈ⮎ℂ⹜㛎ߣߒߡ㧘ਛᨔ␹⚻♽㧘 ᔃⴊ▤♽㧘๭ๆ♽㧘⢗⣺▤♽㧘ⴊዊ᧼෸߮⿒ⴊ⃿ߦኻߔࠆ in vitro ෶ߪ in vivo ૞↪ࠍᬌ⸛ߒߚޕ 1.5.3.2.2 ⮎‛േᘒ⹜㛎 ๆ෼ߦ㑐ߔࠆ⹜㛎ߣߒߡ㧘⚦⢩⤑ㅘㆊᕈ㧘P-♧ߚࠎ⊕⾰㧔P-gp㧕ߦኻߔࠆᓇ㗀෸߮ⴊẏਛ⮎‛ JEDI_DEV00 \ 0900fde980400983 2.4 2013-08-19 13:38 േᘒߦߟ޿ߡᬌ⸛ߒߚޕಽᏓߦ㑐ߔࠆ⹜㛎ߣߒߡ㧘⚵❱ౝỚᐲ㧘ߚࠎ⊕⚿ว㧘ⴊ⃿⒖ⴕ㧘ਗ߮ߦ ⢝ఽ෸߮੃ఽ⒖ⴕߦߟ޿ߡᬌ⸛ߒߚޕઍ⻢ߦ㑐ߔࠆ⹜㛎ߣߒߡ㧘⢄⚦⢩෸߮⢄⚦⢩↹ಽࠍ↪޿ߚ ઍ⻢቟ቯᕈ㧘ⴊẏ㧘♮෸߮⢙᳝ਛઍ⻢‛㧘ઍ⻢㉂⚛㧘ਗ߮ߦ⢄⮎‛ઍ⻢㉂⚛♽߳ߩᓇ㗀ߦߟ޿ߡ ᬌ⸛ߒߚޕឃᴭߦ㑐ߔࠆ⹜㛎ߣߒߡ㧘ࡑࠬࡃ࡜ࡦࠬ෸߮⢙᳝ਛឃᴭߦߟ޿ߡᬌ⸛ߒߚޕ⮎‛േᘒ ቇ⊛⮎‛⋧੕૞↪ߦ㑐ߔࠆ⹜㛎ߣߒߡ㧘ᧄ೷ߣ૬↪ߐࠇࠆน⢻ᕈߩ޽ࠆ⮎‛ߩઍ⻢ߦ෸߷ߔᓇ㗀 ߦߟ޿ߡᬌ⸛ߒߚޕ߹ߚ㧘ࠪࡔࡊ࡟ࡆ࡞ߩઍ⻢ߦ㑐ਈߔࠆਥߥ࠴࠻ࠢࡠ࡯ࡓ P450㧔એਅ㧘 CYP㧕ಽሶ⒳ߪ CYP3A ߢ޽ࠆߎߣ߇␜ߐࠇߚߎߣ߆ࠄ㧘ߎߩ㒖ኂ೷ߣߒߡ⍮ࠄࠇߡ޿ࠆ࡝࠻࠽ ࡆ࡞ࠍ↪޿㧘ࠪࡔࡊ࡟ࡆ࡞ߩⴊẏਛ⮎‛േᘒߦ෸߷ߔᓇ㗀ߦߟ޿ߡ߽ᬌ⸛ߒߚޕᦝߦ㧘ᧄ೷ߩ⥃ ᐥ⹜㛎ߦ߅޿ߡ⹺߼ࠄࠇߚⴊẏਛࡆ࡝࡞ࡆࡦỚᐲ਄᣹ߩ⊒⃻ᯏᐨࠍ᣿ࠄ߆ߦߔࠆߚ߼ߦ㧘ߘߩઁ ߩ⮎‛േᘒ⹜㛎ߣߒߡ㧘ࡆ࡝࡞ࡆࡦߩࠣ࡞ࠢࡠࡦ㉄ᛴว㧘ਗ߮ߦ⢄ขࠅㄟߺ෸߮⢙᳝ਛឃᴭ࠻࡜ ࡦࠬࡐ࡯࠲࡯ߦ㑐ߔࠆᓇ㗀ߦߟ޿ߡᬌ⸛ߒߚޕ 1.5.3.2.3 Ქᕈ⹜㛎 ᕆᕈᲥᕈߪࡑ࠙ࠬ㧔ዊᩭ⹜㛎ߢ⹏ଔ㧕㧘࡜࠶࠻㧘ࠗ࠿෸߮ࠨ࡞ࠍ↪޿ߡ⹏ଔߒߚޕ෻ᓳᛩਈᲥ ᕈߪ㧘ᒝ೙⚻ญᛩਈᲥᕈ⹜㛎ࠍࡑ࠙ࠬ㧔3 ࠞ᦬㑆߹ߢ㧕㧘࡜࠶࠻㧔6 ࠞ᦬㑆߹ߢ㧕㧘ࠗ࠿㧔9 ࠞ᦬ 5 TMC435 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ 㑆߹ߢ㧕෸߮ࠨ࡞㧔1 ࠞ᦬㑆߹ߢ㧕ࠍ↪޿ߡᬌ⸛ߒ㧘ᷙ㙄ᛩਈᲥᕈ⹜㛎ࠍࡑ࠙ࠬ෸߮࡜࠶࠻㧔3 ࠞ᦬㑆߹ߢ㧕ࠍ↪޿ߡᬌ⸛ߒߚޕߔߴߡߩ⹜㛎ߢ࠻ࠠࠪࠦࠠࡀ࠹ࠖࠢࠬࠍ⹏ଔߒߚޕㆮવᲥᕈߪ㧘 in vitro ⹜㛎ߣߒߡ⚦⩶ࠍ↪޿ࠆᓳᏫ⓭ὼᄌ⇣⹜㛎෸߮ࡑ࠙ࠬ࡝ࡦࡈࠜ࡯ࡑ Tk ⹜㛎㧘in vivo ⹜㛎 ߣߒߡࡑ࠙ࠬዊᩭ⹜㛎ߢ⹏ଔߒߚޕ↢ᱺ⊒↢Ქᕈߪ㧘࡜࠶࠻ฃ⢝⢻෸߮⌕ᐥ߹ߢߩೋᦼ⢦⊒↢ߦ 㑐ߔࠆ⹜㛎㧘ࡑ࠙ࠬ෸߮࡜࠶࠻⢦࡮⢝ఽ⊒↢ߦ㑐ߔࠆ⹜㛎㧘࡜࠶࠻಴↢೨෸߮಴↢ᓟߩ⊒↢ਗ߮ ߦᲣ૕ߩᯏ⢻ߦ㑐ߔࠆ⹜㛎ߢ⹏ଔߒߚޕ߹ߚ㧘in vitro ߢ࠙ࠪⷺ⤑ᷙỘ෸߮ㅘㆊᕈ㧔BCOP㧕⹜㛎㧘 శᲥᕈ⹜㛎෸߮⚦⢩Ქᕈ⹜㛎㧘in vivo ߢࡑ࠙ࠬዪᚲ࡝ࡦࡄ▵⹜㛎㧔LLNA㧕㧘࠙ࠨࠡ⊹⤏৻ᰴೝ ỗᕈ⹜㛎෸߮࡜࠶࠻ߦ߅ߌࠆᛩਈน⢻ߥᦨᄢ㊂ߩᬌ⸛⹜㛎ࠍታᣉߒߚޕᦝߦ㧘5 ⒳㘃ߩਇ⚐‛ߦ ߟ޿ߡᲥᕈࠍ⹏ଔߒߚޕਥⷐߥ⹜㛎ߪ GLP ߦḰ᜚ߒߡታᣉߒߚޕ 1.5.3.3 ⥃ᐥ㐿⊒ߩ᭎⇛ C ဳᘟᕈ⢄Ἳߦኻߔࠆ TMC435 ߩ⥃ᐥ㐿⊒ߪ㧘ᶏᄖߢߪ Tibotec Pharmaceuticals Ltd.㧔⃻ Janssen R&D Ireland㧕߇ 20 ᐕࠃࠅ㐿ᆎߒߚޕ࿖ౝߢߪ㧘ࡗࡦ࠮ࡦࡈࠔ࡯ࡑᩣᑼળ␠߇ 20 ᐕ ࠃࠅ╙ II ⋧⹜㛎ࠍ㐿ᆎߒߚޕ⥃ᐥ㐿⊒ߩ᭎⇛ࠍએਅߦ␜ߔޕߥ߅㧘TMC435 ߩ↪㊂ߪࠪࡔࡊ࡟ࡆ ࡞ߣߒߡߩ↪㊂ߢ޽ࠆޕ ߹ߚ㧘޿ߕࠇߩ⥃ᐥ⹜㛎߽㧘ࡋ࡞ࠪࡦࠠት⸒ߩ୶ℂේೣ㧘ᣣ☨ EU ක⮎ຠⷙ೙⺞๺࿖㓙ળ⼏ 㧔ICH㧕ߢวᗧߐࠇߚޟක⮎ຠߩ⥃ᐥ⹜㛎ߩታᣉߩၮḰ㧔GCP㧕ޠ㧘ㆡ↪ߐࠇࠆⷙ೙ⷐઙ෸߮ߘ ࠇߙࠇߩᴦ㛎ታᣉ⸘↹ᦠߦೣߞߡታᣉ࡮ႎ๔ߒߚޕ 1.5.3.3.1 ╙ I ⋧⹜㛎 ᶏᄖߦ߅޿ߡ㧘ੱߢߩ቟ోᕈ෸߮ᔋኈᕈࠍᦨೋߦᬌ⸛ߔࠆ╙ I ⋧⹜㛎ߣߒߡ C101 ⹜㛎ࠍታᣉ ߒߚޕᧄ⹜㛎߆ࠄ㧘ஜᐽᚑੱߦኻߔࠆ TMC435 50㨪600 mg ߩන࿁ᛩਈ෸߮ 100㨪400 mg 1 ᣣ 1 ࿁ ߣ 200 mg 1 ᣣ 2 ࿁ߩ 5 ᣣ㑆෻ᓳᛩਈ㧘ਗ߮ߦ C ဳᘟᕈ⢄Ἳᖚ⠪ߦኻߔࠆ TMC435 200 mg 1 ᣣ 1 JEDI_DEV00 \ 0900fde980400983 2.4 2013-08-19 13:38 ࿁ߩ 5 ᣣ㑆෻ᓳᛩਈߪ㧘߅߅߻ߨ቟ోߢ޽ࠅ㧘ᔋኈᕈߪ⦟ᅢߢ޽ࠆߎߣ߇⏕⹺ߐࠇߚޕ ࿖ౝߢߩ C ဳᘟᕈ⢄Ἳᖚ⠪ࠍኻ⽎ߣߒߚ⥃ᐥ⹜㛎ታᣉߦవ┙ߜ㧘ᶏᄖ࿷૑ߩᣣᧄੱஜᐽᚑੱࠍ ኻ⽎ߣߒߡ╙ I ⋧⹜㛎㧔C109 ⹜㛎㧕ࠍ☨࿖ߢታᣉߒ㧘C101 ⹜㛎ᚑ❣ߣᲧセߒߚޕߘߩ⚿ᨐ㧘ᣣ ᧄੱஜᐽᚑੱߢߪᄖ࿖ੱஜᐽᚑੱߦᲧߴߡ TMC435 ߩหߓᛩਈ㊂ߦኻߒߡ߿߿㜞޿ᦑ㔺㊂߇ᓧࠄ ࠇࠆ௑ะ߇␜ߐࠇߚޕ ߘߩઁߩᣣᧄੱஜᐽᚑੱࠍኻ⽎ߣߒߚ╙ I ⋧⹜㛎ߣߒߡ㧘⋧ኻ⊛ࡃࠗࠝࠕࡌࠗ࡜ࡆ࡝࠹ࠖ⹜㛎 㧔HPC1003 ⹜㛎㧕෸߮㘩੐ߩᓇ㗀ࠍᬌ⸛ߔࠆ⹜㛎㧔HPC1007 ⹜㛎㧕ࠍታᣉߒߚޕ߹ߚᶏᄖߢ㧘 QT/QTc ߦኻߔࠆᓇ㗀ࠍᬌ⸛ߔࠆ⹜㛎㧔C117 ⹜㛎㧕ࠍታᣉߒ㧘ߘߩઁ㧘⋧ኻ⊛ࡃࠗࠝࠕࡌࠗ࡜ࡆ ࡝࠹ࠖ⹜㛎㧔3 ⹜㛎㧕㧘㘩੐ߩᓇ㗀ࠍᬌ⸛ߔࠆ⹜㛎㧔2 ⹜㛎㧕㧘ࡑࠬࡃ࡜ࡦࠬ⹜㛎㧔1 ⹜㛎㧕㧘․ ᱶᖚ⠪㧔⢄ᯏ⢻㓚ኂᖚ⠪෸߮⣢ᯏ⢻㓚ኂᖚ⠪㧕ߩ⮎‛േᘒࠍᬌ⸛ߔࠆ⹜㛎㧔ฦ 1 ⹜㛎㧕㧘⮎‛േ ᘒቇ⊛⮎‛⋧੕૞↪⹜㛎㧔12 ⹜㛎㧕෸߮శ቟ోᕈ⹜㛎㧔1 ⹜㛎㧕ࠍታᣉߒߚޕ 6 TMC435 1.5 ⿠ේ෶ߪ⊒⷗ߩ⚻✲෸߮㐿⊒ߩ⚻✲ 1.5.3.3.2 ╙ II ⋧⹜㛎 ᶏᄖߦ߅޿ߡ㧘Genotype 1 ဳ C ဳᘟᕈ⢄Ἳߩೋ࿁ᴦ≮ᖚ⠪෸߮ᣢᴦ≮ᖚ⠪ࠍኻ⽎ߦ㧘TMC435 න೷ᛩਈߒߚߣ߈ਗ߮ߦ PegIFNĮ-2a ෸߮ RBV ߣ૬↪ᛩਈߒߚߣ߈ߩ᛫࠙ࠗ࡞ࠬലᨐߦ߅ߌࠆ↪ ㊂ଐሽᕈ෸߮቟ోᕈࠍᬌ⸛ߔࠆ⋡⊛ߢ㧘Proof-of-Principle ⹜㛎㧔C201 ⹜㛎㧕ࠍ⸘↹ߒߚޕೋ࿁ᴦ ≮଀ߦኻߒ㧘TMC435 ࠍන೷ߢ 7 ᣣ㑆ᛩਈᓟ㧘PegIFNĮ-2a ෸߮ RBV ߣߩ 3 ೷૬↪ߢ 21 ᣣ㑆ᛩਈ ߔࠆߎߣߣߒߚޕ߹ߚ㧘ೋ࿁ᴦ≮଀෸߮ᣢᴦ≮଀ߦኻߒߡ㧘TMC435 ࠍ PegIFNĮ-2a ෸߮ RBV ߣ ߩ 3 ೷૬↪ߢ 28 ᣣ㑆ᛩਈߒߚޕߘߩ⚿ᨐ㧘ೋ࿁ᴦ≮଀ߦ߅ߌࠆ 3 ೷૬↪ᛩਈߢߪ㧘ᛩਈ 7 ᣣ⋡ ߩ HCV RNA ㊂ߩࡌ࡯ࠬ࡜ࠗࡦ߆ࠄߩᷫዋ㊂߇ TMC435 න೷ᛩਈࠃࠅᄢ߈ߊ㧘ᛩਈ 4 ㅳߩ HCV RNA ㊂ߩࡌ࡯ࠬ࡜ࠗࡦ߆ࠄߩᷫዋ㊂ߪ TMC435 75 mg ෸߮ 200 mg ᛩਈߢ߶߷ห⒟ᐲߢ޽ߞߚޕ ৻ᣇ㧘ᣢᴦ≮଀ߦ߅޿ߡ㧘ᛩਈ 4 ㅳߩ HCV RNA ㊂ߩࡌ࡯ࠬ࡜ࠗࡦ߆ࠄߩᷫዋ㊂ߪ㧘TMC435 150 mg ෸߮ 200 mg ᛩਈߦᲧߴߡ 75 mg ᛩਈߢዊߐ߆ߞߚޕ߹ߚ㧘TMC435 ߩ↪㊂෸߮ᦑ㔺㊂ߦ ଐሽߒߚⴊਛࡆ࡝࡞ࡆࡦ୯ߩ਄᣹߇ߺࠄࠇ㧘200 mg ᛩਈߢࠃࠅ㗼⪺ߢ޽ߞߚޕ ⛯޿ߡ㧘࿖ౝߦ߅ߌࠆᦨೋߩ⥃ᐥ⹜㛎ߣߒߡ㧘Genotype 1 ဳ㜞࠙ࠗ࡞ࠬ㊂ߩ C ဳᘟᕈ⢄Ἳߩೋ ࿁ᴦ≮ᖚ⠪ࠍኻ⽎ߦ㧘TMC435 ࠍ PegIFNĮ-2a ෸߮ RBV ߣ૬↪ߒߚߣ߈ߩ᦭ലᕈ෸߮቟ోᕈࠍᬌ ⸛ߔࠆ⋡⊛ߢ╙ II ⋧⹜㛎㧔C215 ⹜㛎㧕ࠍ㧘㕖⋤ᬌ⹜㛎ߣߒߡ⸘↹ߒߚޕTMC435 ߩ↪ᴺ࡮↪㊂
Load more

Recommended publications
  • CVMP Assessment Report for APOQUEL (EMEA/V/C/002688/0000) International Non-Proprietary Name: Oclacitinib Maleate
    18 July 2013 EMA/481054/2013 Veterinary Medicines and Product Data Management Committee for Medicinal Products for Veterinary Use CVMP assessment report for APOQUEL (EMEA/V/C/002688/0000) International non-proprietary name: oclacitinib maleate Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8447 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Introduction The applicant Pfizer Animal Health S.A. submitted on 26 July 2012 an application for marketing authorisation to the European Medicines Agency (The Agency) for APOQUEL, through the centralised procedure falling within Article 3(2)(a) of Regulation (EC) No 726/2004 (new active substance). During the procedure the applicant changed to Zoetis Belgium S.A. The eligibility to the centralised procedure was confirmed by the CVMP on 12 January 2012 falling under Article 3(2)(a) of Regulation (EC) No 726/2004 as APOQUEL contains a new active substance which was not authorised in the Community on the date of entry into force of the Regulation. APOQUEL film-coated tablets contain oclacitinib (as oclacitinib maleate) as the active substance. There are three different strengths of the (film-coated) tablets, containing 3.6 mg, 5.4 mg and 16 mg oclacitinib (as the maleate salt), and each is contained in blister packs (polychlorotrifluoroethylene (PCTFE)/polyvinylchloride (PVC)/aluminium) which are supplied in outer cartons containing 20 or 100 tablets.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • 5.10.20 Final Part 1 No Prelimeary Pages
    IDENTIFICATION OF NOVEL TREATMENT APPROACHES FOR HUMAN AND CANINE OSTEOSARCOMA By Ya-Ting Yang A DISSERTATION Submitted to Michigan State University in partial fulfillment of the requirements for the degree of Comparative Medicine and Integrative Biology- Doctor of Philosophy 2020 ABSTRACT IDENTIFICATION OF NOVEL TREATMENT APPROACHES FOR HUMAN AND CANINE OSTEOSARCOMA By Ya-Ting Yang Osteosarcoma (OSA) is an aggressive neoplasm, characterized with high level of heterogeneity, high metastatic potential and poor prognosis in both humans and dogs. In this study, I used drug screening studies including existing therapeutic agents and novel compounds to identify more effective approaches to treat human and canine osteosarcoma. One of the challenges in the field of OSA is to identify optimal tools for study. A limited number of human and canine OSA cell lines are available. In this study, I established and characterized a new cell line, BZ, derived from a German shepherd dog with OSA and studied key oncogenic pathways in BZ. Our findings revealed activation of STAT3 and ERK pathways in BZ, as well as in a number of other cell lines, indicating that these two pathways are critical for cell survival and proliferation in OSA and the potential of using STAT3 and ERK inhibitors. Furthermore, I screened ten tyrosine kinase inhibitors (TKIs) on two dog and one human OSA cell lines. Among the selected TKIs, sorafenib showed promising results in effectively inhibited cell growth and migration in vitro studies. In addition, the effects of combing sorafenib with current chemotherapeutics (cisplatin, carboplatin, and doxorubicin) for OSA were investigated. Data from the combination index pointed to synergistic effects of sorafenib combined with doxorubicin and resulted in profound cell arrest at G2/M phase.
    [Show full text]
  • Successful Treatment of Atopic Dermatitis with the JAK1 Inhibitor Oclacitinib
    PROC (BAYL UNIV MED CENT) 2018;31(4):524–525 Copyright # 2018 Baylor University Medical Center https://doi.org/10.1080/08998280.2018.1480246 Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib Isabel M. Haugh, MB, BAO, BCha, Ian T. Watson,b and M. Alan Menter, MDa aDepartment of Dermatology, Baylor University Medical Center, Dallas, Texas; bTexas A&M College of Medicine, Bryan, Texas ABSTRACT We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treat- ment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans. KEYWORDS Atopic dermatitis; eczema; JAK1; oclacitinib clacitinib is a Janus kinase-1 (JAK1) inhibitor DISCUSSION approved for the treatment of pruritus secondary Oclacitinib selectively inhibits JAK1 of the JAK signal O to allergic dermatitis and atopic dermatitis in transducer and activator of transcription (JAK-STAT) path- canines. JAK1 plays a role in the expression of way, which plays a central role in cytokine signaling of pro- interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 inflammatory cytokines in atopic dermatitis, both in dogs (IL-13) in proinflammatory signaling pathways known to and in humans.
    [Show full text]
  • Safety and Toxicity of Combined Oclacitinib and Carboplatin Or Doxorubicin in Dogs with Solid Tumors: a Pilot Study Laura E
    Barrett et al. BMC Veterinary Research (2019) 15:291 https://doi.org/10.1186/s12917-019-2032-4 RESEARCH ARTICLE Open Access Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study Laura E. Barrett1, Heather L. Gardner2, Lisa G. Barber1, Abbey Sadowski1 and Cheryl A. London1* Abstract Background: Oclacitinib is an orally bioavailable Janus Kinase (JAK) inhibitor approved for the treatment of canine atopic dermatitis. Aberrant JAK/ Signal Transducer and Activator of Transcription (STAT) signaling within hematologic and solid tumors has been implicated as a driver of tumor growth through effects on the local microenvironment, enhancing angiogenesis, immune suppression, among others. A combination of JAK/STAT inhibition with cytotoxic chemotherapy may therefore result in synergistic anti-cancer activity, however there is concern for enhanced toxicities. The purpose of this study was to evaluate the safety profile of oclacitinib given in combination with either carboplatin or doxorubicin in tumor-bearing dogs. Result: Oclacitinib was administered at the label dose of 0.4–0.6 mg/kg PO q12h in combination with either carboplatin at 250-300 mg/m2 or doxorubicin at 30 mg/m2 IV q21d. Nine dogs were enrolled in this pilot study (n =4 carboplatin; n = 5 doxorubicin). No unexpected toxicities occurred, and the incidence of adverse events with combination therapy was not increased beyond that expected in dogs treated with single agent chemotherapy. Serious adverse events included one Grade 4 thrombocytopenia and one Grade 4 neutropenia. No objective responses were noted. Conclusions: Oclacitinib is well tolerated when given in combination with carboplatin or doxorubicin.
    [Show full text]
  • TITLE PAGE PASS Information
    TITLE PAGE PASS information Title Project Sc(y)lla: SARS-Cov-2 Large-scale Longitudinal Analyses on the comparative safety and effectiveness of treatments under evaluation for COVID-19 across an international observational data network Protocol version 1.1 identifier Date of last version of 28August2020 protocol EU PAS register number To be completed after protocol finalization Active substance Medicinal product Research question and The overarching objective is to evaluate the objectives comparative effects of COVID-19 treatments Country(-ies) of study France, Germany, Netherlands, South Korea, Spain, UK, and the USA. Others might join in the future. Authors Patrick Ryan Daniel Prieto-Alhambra on behalf of the OHDSI COVID consortium 1. TABLE OF CONTENTS 1. Table of contents ............................................................................................................................................. 2 2. List of abbreviations......................................................................................................................................... 3 3. Responsible parties .......................................................................................................................................... 3 5. Amendments and updates .............................................................................................................................. 4 7 Rationale and background...............................................................................................................................
    [Show full text]
  • APOQUEL® (Oclacitinib Tablet): Fast-Acting and Safe Itch Relief For
    APOQUEL® (oclacitinib tablet): Fast-Acting and Safe Itch Relief for Dogs Your veterinarian has recommended APOQUEL to help control your dog’s itch due to allergic skin disease. APOQUEL provides fast, effective relief from itch and inflammation without many of the side effects associated with steroids.1-3* *Common side effects of steroids include polyuria, polydipsia and polyphagia. Side effects of APOQUEL reported most often are vomiting and diarrhea. WHAT IS ALLERGIC SKIN DISEASE? Itching in dogs can be caused by fleas, food or environmental allergens such as pollens, molds or house-dust mites. The 4 most common allergies are: CONTACT ALLERGY ENVIRONMENTAL INDOOR FLEA FOOD (carpet, shampoo, AND OUTDOOR ALLERGENS ALLERGY ALLERGY environmental chemicals— (pollen, dust mites, or mold) insecticides, fertilizers) WHAT IS APOQUEL USED FOR? APOQUEL is used for the control of itch associated with allergic skin disease and for control of atopic skin disease in dogs at least 12 months of age. APOQUEL significantly reduces itching, and also decreases the associated inflammation, redness or swelling of the skin. WHAT CAN I EXPECT WHEN MY DOG RECEIVES APOQUEL? Fast Relief Unique Treatment APOQUEL starts to relieve itch within 4 hours, Unlike other treatments, APOQUEL targets a key itch signal in which is comparable to steroids. 3 the nervous system and has minimal impact on the immune system. APOQUEL effectively controls itch within 24 hours.1 APOQUEL also allows your veterinarian to continue to diagnose the underlying cause of itch while providing your dog with relief. 3,4 Safety APOQUEL is safe to use in dogs 12 months of age and older.
    [Show full text]
  • Perspektive 2023
    Perspektive 2023 Neue Medikamente in Entwicklung Inhalt 2 Neue Medikamente in Sicht 6 Neue Wege 8 Neue Chancen für Krebspatienten 10 Entzündungen zum Erliegen bringen 13 Infektionen bekämpfen 14 Gegen Krankheiten unterschiedlichster Art 16 Kindermedikamente und Orphan Drugs 19 Medikamente für Männer und Frauen 20 Die neuen Wirkstoffe 23 Der Beitrag Deutschlands 26 Projekte, die bis 2023 zu einer Zulassung führen können 44 Schwerpunkte der vfa-Mitglieder 46 Kontakt Blick voraus Mehr als zehn Jahre dauert es von der Idee bis zur Zulassung, manch- mal mehr als zwanzig. Erfolge mit neuen Medikamenten kann also nur ernten, wer lange vorher gesät hat. Das haben die forschenden Pharma-Unternehmen des vfa in den späten 2000er- und frühen 2010er-Jahren reichlich getan, so dass nun besonders viele Medika- mente in ihrer Erprobung weit fort geschritten sind. Welche es noch vor Ende 2023 bis zu einer Zulassung oder Zulassungserweiterung schaffen könnten, zeigt diese Veröffentlichung. Sie macht deutlich, dass zahlreiche Patientinnen und Patienten gute Aussichten auf bessere Behandlungsmöglich keiten für ihre Leiden haben. vfa – die forschenden Pharma-Unternehmen Perspektive 2023 Neue Medikamente in Sicht Viele Krankheiten sind in den letzten Jahren besser behandelbar geworden, und Patienten und Ärzte hoffen, dass dieser Strom des Fortschritts nicht abreißt. Die Chancen dafür stehen gut. Denn forschende Pharma-Unternehmen entwickeln derzeit gegen mehr als 145 Krankheiten Medikamente, die bis spätestens Ende 2023 die Zulassung erhalten könnten. Das zeigt eine Erhebung des vfa bei seinen Mitgliedsunter nehmen vom Oktober 2019. Demnach könnten bis Ende 2023 insgesamt 434 Sämtliche Projekte, die in der Erhebung erfasst ihrer Projekte zu einer Zulassung oder Zulassungs- wurden, sind ab S.
    [Show full text]
  • Development and Progression of Proteinuria in Dogs Treated with Masitinib for Neoplasia: 28 Cases (2010-2019)
    / PAPER Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010-2019) M. Kuijlaars1,*, J. Helm* and A. McBrearty* a.com *Small Animal Hospital, University of Glasgow, Glasgow, Scotland, G611QH, UK 1Corresponding author email: [email protected] v OBJECTIVES: To describe the incidence, severity and progression of proteinuria over the first 6 months of masitinib treatment in tumour-bearing dogs without pre-existing proteinuria. To describe the effect of treatment on urine protein:creatinine and renal parameters in patients with pre-existing proteinuria. MATERIALS AND METHODS: Records were reviewed from patients receiving masitinib for neoplasms between June 1, 2010, and May 5, 2019. Patients without pre-treatment and at least one urine protein:creatinine after ≥7 days treatment were excluded. Signalment, tumours and concurrent diseas- es, treatments, haematology, biochemistry and urinalysis results before, during and after treatment for up to 202 days were collected. Patient visits were grouped into six timepoints for analysis. .bsa RESULTS: Twenty-eight dogs were included. Eighteen percent of dogs non-proteinuric at baseline (four of 22) developed proteinuria during treatment, all within 1 month of treatment initiation. One dog developed hypoalbuminaemia, none developed oedema or ascites, azotaemia or were euthana- sed/died due to proteinuria. Masitinib was immediately discontinued in both dogs in which urine protein:creatinine greater than 2.0 was detected and in both, proteinuria improved. Six dogs with pre-treatment proteinuria were treated with masitinib, significant worsening of protein- uria did not occur. Neither azotaemia nor severe hypoalbuminaemia occurred. CLINICAL SIGNIFICANCE: Proteinuria, when it occurs, tends to develop within 1 month of masitinib com- mencement and may progress rapidly.
    [Show full text]
  • DMM Model of Osteoarthritis
    WHY DOES MY JOINT HURT: UNDERSTANDING DISEASE PHENOTYPE AND PAIN RELATIONSHIPS USING MOUSE MODELS OF ARTHRITIS Sanaa Zaki A thesis submitted in fulfilment of requirements for the degree of Doctor of Philosophy Faculty of Medicine (Sydney Medical School) The University of Sydney November 2016 i PREFACE The research embodied in this thesis was conducted at the Raymond Purves Laboratories of Bone and Joint Research, Kolling Institute of Medical Research, University of Sydney at the Royal North Shore Hospital, St Leonards, Australia. Institutional ethics committee approval was sought and obtained prior to the commencement of all animal experiments. The research was partly funded by Arthritis Australia. I certify that the intellectual content of this thesis is the product of my own work, including the design, conduct and analysis of experiments presented in this thesis. Contributions of other researchers and all the assistance received in preparing this thesis and relevant sources have been acknowledged. This thesis has not been submitted for any degree or other purpose. Sanaa Zaki ii ACKNOWLEDGEMENTS My PhD candidature has been a very long journey and I have many colleagues, friends and family that I need to acknowledge for their contribution. Firstly, I am forever indebted to the support and mentorship of my two supervisors, Mark Connor and Chris Little. They graciously bestowed me with the freedom to pave my own path of scientific discovery, while always being there to guide and redirect me when I needed it the most. I am truly indebted to their academic brilliance, scientific rigor and boundless patience. They are truly inspirational researchers that I can only hope to, one day, emulate.
    [Show full text]
  • Recombinant Human Interferon-Alpha 14 for the Treatment of Canine
    Received: 8 June 2020 Revised: 15 January 2021 Accepted: 3 February 2021 DOI: 10.1002/vro2.6 RESEARCH ARTICLE Recombinant human interferon-α for the treatment of canine allergic pruritic disease in eight dogs Breno C. B. Beirão, Aline C. Taraciuk Carolina Trentin Max Ingberman Luiz F. Caron Chris McKenzie William H. Stimson, 1 Imunova Análises Biológicas LTDA, Curitiba, Abstract Brazil Background: Allergic pruritic diseases are increasingly common in dogs. This group 2 Departamento de Patologia Básica, Universidade of conditions hampers life quality as pruritus progressively interferes with normal Federal do Paraná, Curitiba, Brazil behaviours. Therefore, new treatment modalities for canine allergic pruritic diseases are 3 Veterinary Consultant, Avenida Nossa Senhora necessary. While novel drugs have recently reached the market, there is still the need for de Lourdes,63, Curitiba, Brazil other therapeutic approaches. Some dogs are refractory even to the newer compounds, 4 ILC Therapeutics Ltd. Biocity, Scotland, and cost is also an important issue for these. Older therapeutic modalities are only mod- Lanarkshire, UK erately successful or have considerable secondary efects, as is the case with glucocorti- 5 Immunology Department, Strathclyde University, Glasgow, Scotland, UK coids. Objectives: Report on the use of recombinant human interferon-α14 (rhIFN-α14) for Correspondence the treatment of canine allergic pruritus. Following the experience with a similar com- BrenoC.B.Beirão,ImunovaAnálisesBiológicas pound in the Japanese market, it was expected that rhIFN-α14couldaltertheTh1/Th2 LTDA,R.ImaculadaConceição,1430,Curitiba, disbalance that drives these diseases. 80215-182, Brazil. Email: [email protected] Methods: Here, we present an uncontrolled trial in which eight dogs with clinical diag- nosis of allergic pruritus were treated with rhIFN-α14,eitherorallyorviasubcutaneous Funding information: Imunova Análises Biológi- injections.
    [Show full text]